MedTrace Logo

Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis

NCT00592566 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2008-01-14

No results posted yet for this study

Summary

Background: Pulmonary involvement in leptospirosis has been reported to be on the increase and is emerging as the main cause of death due to leptospirosis in many countries, including Thailand.

Methods: A prospective randomized controlled trial of desmopressin or high dose dexamethasone as adjunctive therapy in patients with suspected pulmonary hemorrhage associated with leptospirosis was conducted between July 2003 and October 2006 at 5 hospitals in Thailand.

Conditions

  • Leptospirosis

Interventions

DRUG

Dexamethasone, desmopressin

200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion

Sponsors & Collaborators

  • Thailand Research Fund

    collaborator OTHER

  • Mahidol University

    lead OTHER

Principal Investigators

  • Kanigar Niwattayakul, MD · Loei Hospital, Loei, Thailand:

  • Yupin Suputtamongkol, MD · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00592566 on ClinicalTrials.gov